Pathogenesis, Lethality, and Immunizing Effect of Experimental Cutaneous Cryptococcosis

Mice were subcutaneously inoculated with small numbers of virulent Cryptococcus neoformans and divided into groups. Numbers of viable yeasts at the site were estimated at weekly intervals for 5 weeks on the basis of cultures of minced tissue excised from sacrificed animals. Organisms multiplied at the site for at least 4 weeks and were still detectable after the 5th week, although in reduced numbers. Agglutinins appeared within a week, but these antibodies were not detectable during the 2nd through the 5th week. Cryptococcal polysaccharide began to appear in the sera at 3 weeks, persisting through the duration of 5 weeks. All animals appeared healthy, but a few sickened after many months and died of systemic cryptococcosis. All of these events were observed in many separate experiments. The immunizing capacity of a cutaneous lesion was tested by challenging some of the above animals with viable C. neoformans after various intervals of time, either subcutaneously at a site distant from that of the vaccination or intravenously. Although we were unable to demonstrate reduced multiplication of yeasts in the brains, lungs, and spleens of intravenously challenged animals, it was possible to show that multiplication was inhibited at the site of subcutaneous challenge. It was noted also that vaccinated animals lived longer after lethal intravenous challenge than did nonvaccinated animals. The latter protection was observed, however, only when challenge followed vaccination by 3 weeks or longer, and it was effective only against a relatively low challenge dose. Mice were protected against a higher dose if they had previously received killed cryptococci, alternating subcutaneous and intraperitoneal inoculations, one of which contained a microbial adjuvant. No protection was observed in animals that were subcutaneously vaccinated with inert materials such as chitin, latex spheres, or even cryptococcal cell walls themselves.

[1]  M. Dykstra,et al.  Capsule size of Cryptococcus neoformans: control and relationship to virulence , 1977, Infection and immunity.

[2]  K. Kwon-Chung A new genus, filobasidiella, the perfect state of Cryptococcus neoformans. , 1975, Mycologia.

[3]  M. Song Experimental cryptococcosis of the skin. , 1974, Sabouraudia.

[4]  J. Murphy,et al.  Skin Testing of Guinea Pigs and Footpad Testing of Mice With a New Antigen for Detecting Delayed Hypersensitivity to Cryptococcus neoformans , 1974, Infection and immunity.

[5]  T. G. Mitchell,et al.  In Vitro Phagocytosis and Intracellular Fate of Variously Encapsulated Strains of Cryptococcus neoformans , 1972, Infection and immunity.

[6]  L. F. Fajardo,et al.  Primary cutaneous cryptococcosis: review and morphologic study. , 1972, American journal of clinical pathology.

[7]  G. Bulmer,et al.  Cryptococcus neoformans IV. The Not-So-Encapsulated Yeast , 1970, Infection and immunity.

[8]  K. Warren,et al.  THE ROLE OF CHEMICAL MEDIATORS IN THE INFLAMMATORY RESPONSE INDUCED BY FOREIGN BODIES: COMPARISON WITH THE SCHISTOSOME EGG GRANULOMA , 1970, The Journal of experimental medicine.

[9]  L. Kaufman,et al.  Value and interpretation of serological tests for the diagnosis of cryptococcosis. , 1968, Applied microbiology.

[10]  H. Muchmore,et al.  Delayed hypersensitivity to cryptococcin in man. , 1968, Sabouraudia.

[11]  A. Atkinson,et al.  Experience with a new skin test antigen prepared from Cryptococcus neoformans. , 1968, The American review of respiratory disease.

[12]  I. Abrahams Further studies on acquired resistance to murine cryptococcosis: enhancing effect of Bordetella pertussis. , 1966, Journal of immunology.

[13]  M. Gordon,et al.  Detection of Cryptococcus neoformans Antigen in Body Fluids by Latex Particle Agglutination.∗ , 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[14]  J. W. Wilson Cutaneous (chancriform) syndrome in deep mycoses. , 1963, Archives of dermatology.

[15]  H. Gadebusch Specific degradation of Cryptococcus neoformans 3723 capsular polysaccharide by a microbial enzyme. III. Antibody stimulation by partially decapsulated cells. , 1960, The Journal of infectious diseases.

[16]  H. Gadebusch,et al.  Passive Immunization Against Cryptococcus neoformans. ∗ , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  S. Levine,et al.  Experimental cryptococcosis (torulosis). , 1957, The American journal of pathology.

[18]  F. Ellis,et al.  Pulmonary cryptococcosis. , 1957, The New England journal of medicine.

[19]  I. Abrahams,et al.  A COMPARISON OF THE IMMUNOGENICITY OF WEAKLY ENCAPSULATED AND OF STRONGLY ENCAPSULATED STRAINS OF CRYPTOCOCCUS NEOFORMANS (TORULA HISTOLYTICA) , 1950, Journal of bacteriology.

[20]  L. Stevenson,et al.  Torula Infection * , 1941, The Yale journal of biology and medicine.